File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pharmacokinetics of repeated doses of misoprostol

TitlePharmacokinetics of repeated doses of misoprostol
Authors
KeywordsMisoprostol
Pharmacokinetics
Sublingual
Vaginal
Issue Date2009
PublisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/
Citation
Human Reproduction, 2009, v. 24 n. 8, p. 1862-1869 How to Cite?
AbstractBACKGROUNDMisoprostol is widely used in obstetrics and gynaecology for medical abortion, cervical priming and induction of labour. To aid the design of effective and safe regimens, we have investigated the pharmacokinetic parameters after the vaginal or sublingual administration of repeated doses of 400 g of misoprostol.METHODSWomen undergoing termination of pregnancy by suction evacuation were randomized to receive 400 g of sublingual or vaginal misoprostol every 3 h for five doses. Venous blood was taken at 180, 200, 240, 360, 380, 420, 540, 560, 600, 720, 740, 780 and 900 min after the first dose of misoprostol for determination of the plasma level of misoprostol acid (MPA).RESULTSThe peak plasma levels of MPA decreased with successive doses of vaginal misoprostol, whereas the peak plasma levels were similar with successive doses of sublingual misoprostol. After the third dose, the peak plasma levels of MPA after sublingual misoprostol were significantly higher than those after vaginal administration. After the final dose, the area under the MPA concentration-time curve after sublingual administration was significantly higher than that after vaginal misoprostol (P < 0.031). However, subgroup analysis in the vaginal administration group showed that the progressive decline in the peak plasma levels of MPA occurred only in women with significant vaginal bleeding.CONCLUSIONSThe peak plasma level of MPA after each dose of misoprostol is higher and the bioavailability is also greater after sublingual administration, compared with that after vaginal administration, of repeated doses of misoprostol. The difference was probably due to the reduction in absorption of vaginal misoprostol in the presence of significant vaginal bleeding.
Persistent Identifierhttp://hdl.handle.net/10722/125556
ISSN
2015 Impact Factor: 4.621
2015 SCImago Journal Rankings: 2.271
ISI Accession Number ID
Funding AgencyGrant Number
Research Group of Post-ovulatory Methods for Fertility Regulation of the UNDP/UNFPA/WHO/World Bank
Funding Information:

The work described in this paper was fully supported by Research Group of Post-ovulatory Methods for Fertility Regulation of the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human reproduction.

References

 

DC FieldValueLanguage
dc.contributor.authorTang, OSen_HK
dc.contributor.authorSchweer, Hen_HK
dc.contributor.authorLee, SWHen_HK
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2010-10-31T11:38:05Z-
dc.date.available2010-10-31T11:38:05Z-
dc.date.issued2009en_HK
dc.identifier.citationHuman Reproduction, 2009, v. 24 n. 8, p. 1862-1869en_HK
dc.identifier.issn0268-1161en_HK
dc.identifier.urihttp://hdl.handle.net/10722/125556-
dc.description.abstractBACKGROUNDMisoprostol is widely used in obstetrics and gynaecology for medical abortion, cervical priming and induction of labour. To aid the design of effective and safe regimens, we have investigated the pharmacokinetic parameters after the vaginal or sublingual administration of repeated doses of 400 g of misoprostol.METHODSWomen undergoing termination of pregnancy by suction evacuation were randomized to receive 400 g of sublingual or vaginal misoprostol every 3 h for five doses. Venous blood was taken at 180, 200, 240, 360, 380, 420, 540, 560, 600, 720, 740, 780 and 900 min after the first dose of misoprostol for determination of the plasma level of misoprostol acid (MPA).RESULTSThe peak plasma levels of MPA decreased with successive doses of vaginal misoprostol, whereas the peak plasma levels were similar with successive doses of sublingual misoprostol. After the third dose, the peak plasma levels of MPA after sublingual misoprostol were significantly higher than those after vaginal administration. After the final dose, the area under the MPA concentration-time curve after sublingual administration was significantly higher than that after vaginal misoprostol (P < 0.031). However, subgroup analysis in the vaginal administration group showed that the progressive decline in the peak plasma levels of MPA occurred only in women with significant vaginal bleeding.CONCLUSIONSThe peak plasma level of MPA after each dose of misoprostol is higher and the bioavailability is also greater after sublingual administration, compared with that after vaginal administration, of repeated doses of misoprostol. The difference was probably due to the reduction in absorption of vaginal misoprostol in the presence of significant vaginal bleeding.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/en_HK
dc.relation.ispartofHuman Reproductionen_HK
dc.rightsThis is a pre-copy-editing, author-produced PDF of an article accepted for publication in Human Reproduction following peer review. The definitive publisher-authenticated version Human Reproduction, 2009, v. 24 n. 8, p. 1862-1869 is available online at: http://dx.doi.org/10.1093/humrep/dep108-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectMisoprostolen_HK
dc.subjectPharmacokineticsen_HK
dc.subjectSublingualen_HK
dc.subjectVaginalen_HK
dc.subject.meshAbortifacient Agents, Nonsteroidal - administration and dosage - pharmacokinetics-
dc.subject.meshAdministration, Intravaginal-
dc.subject.meshAdministration, Sublingual-
dc.subject.meshMisoprostol - administration and dosage - analogs and derivatives - blood - pharmacokinetics-
dc.subject.meshPregnancy-
dc.titlePharmacokinetics of repeated doses of misoprostolen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0268-1161&volume=24&issue=8&spage=1862&epage=1869&date=2009&atitle=Pharmacokinetics+of+repeated+doses+of+misoprostolen_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturepostprint-
dc.identifier.doi10.1093/humrep/dep108en_HK
dc.identifier.pmid19395364-
dc.identifier.scopuseid_2-s2.0-67651092226en_HK
dc.identifier.hkuros181343en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-67651092226&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume24en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1862en_HK
dc.identifier.epage1869en_HK
dc.identifier.eissn1460-2350-
dc.identifier.isiWOS:000268111300011-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridTang, OS=7006723402en_HK
dc.identifier.scopusauthoridSchweer, H=7006657959en_HK
dc.identifier.scopusauthoridLee, SWH=26030998000en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats